Hematology Frontier

From January 3–5, 2025, the 5th Annual Meeting of Chinese Alliance for Societies of Hematology (CASH) was held in Tianjin under the theme “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being.” As a key highlight of the conference, the Top 10 Hematology Research Advancements of 2024 were announced during the closing ceremony, recognizing significant scientific achievements in the field of hematology over the past year.

In recent years, the field of hematologic oncology has witnessed remarkable breakthroughs, with acute lymphoblastic leukemia (ALL) emerging as a focal point of progress. Chinese researchers have made significant contributions, driving milestone advancements in both research and clinical practice. To usher in the new year, Hematology Frontier invited Professor Jun Ma from the Harbin Institute of Hematology and Oncology to provide an in-depth review of the key developments in ALL during 2024. This comprehensive analysis aims to guide clinical practice and inspire future research.

In recent years, the field of hematologic oncology has experienced remarkable breakthroughs, with significant advancements in mantle cell lymphoma (MCL). Chinese researchers have increasingly contributed to this progress, playing a pivotal role in driving academic development and clinical practice in the field. As we step into the new year, Hematology Frontier invited Professor Shuhua Yi from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to review the major events and breakthroughs in MCL during 2024. This comprehensive summary aims to provide valuable insights for clinical practice and future research directions.

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) took place in Hangzhou, China, attracting top experts, scholars, and industry leaders in the fields of cell…

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was held in Hangzhou, China, bringing together global leaders in cell and immunotherapy. This conference served as…

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was held in Hangzhou, China, bringing together leading experts, scholars, and industry leaders in the fields of…

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was held in Hangzhou, China. The event gathered top experts, scholars, and industry leaders in cellular and…

The 66th American Society of Hematology (ASH) Annual Meeting was held from December 7–10, 2024, in San Diego, USA. As one of the world's largest international academic conferences in the field of hematology, ASH brings together cutting-edge research and the latest drug development data, showcasing the highest level of global hematology research. During this event, Dr. Kai Hu, Director of the Lymphoma and Myeloma Department at Beijing GoBroad Boren Hospital, had multiple studies (abstracts 3079, 3387, and 1745) selected for presentation, focusing on CAR-T therapy in lymphoma and myeloma. Oncology Frontier – Hematology Frontier invited Professor Hu to share in-depth insights and analyses on these studies

The 66th American Society of Hematology (ASH) Annual Meeting was held from December 7–10, 2024, in San Diego, USA. As one of the largest global academic events in hematology, it showcased cutting-edge research and the latest drug development data. At this prestigious conference, Dr. Zhihui Li from Beijing GoBroad Boren Hospital (Dr. Tong Wu ’s team) presented an oral abstract (Abstract 599) investigating the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in advanced natural killer/T-cell lymphoma (NKTCL) and analyzing prognostic factors affecting transplantation outcomes. Hematology Frontier  invited Professor Li to provide in-depth insights into this study.

The 66th Annual Meeting of the American Society of Hematology (ASH) was held from December 7 to 10, 2024, in San Diego, USA. This global event brought together leading experts in hematology to discuss the latest advancements in the field. At the meeting, the team led by Dr. Ruidong Zhang from Beijing Children’s Hospital，Capital Medical University presented significant findings (Abstract O312) on the treatment of pediatric B-cell acute lymphoblastic leukemia (B-ALL), providing fresh insights and possibilities for future therapies. Hematology Frontier invited Dr. Peijing Qi, the study's lead investigator, to provide an in-depth analysis of the research and its implications for clinical practice.